Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach
Abstract
:1. INTRODUCTION
2. A STEP-BY-STEP APPROACH: CHOOSING THE BEST TREATMENT OPTION FOR EVERY LINE OF THERAPY
2.1. The Beginning: First-Line Treatment
2.1.1. Chemotherapy in First Line
2.1.2. Targeted Therapies in First Line
2.1.3. Evidence-Based Medicine: A Rational Approach in First Line
2.2. Continuing the Efficacy Benefit: Maintenance
2.2.1. Chemotherapy in Maintenance
2.2.2. Targeted Therapies in Maintenance
2.2.3. Combining Agents to Maximize Benefit: Future Directions in Maintenance Therapy
2.2.4. Evidence-Based Medicine: A Rational Approach in Maintenance
2.3. A Step Further: Second Line
2.3.1. Chemotherapy in Second Line
2.3.2. Targeted Therapies in Second Line
2.3.3. Evidence-Based Medicine: A Rational Approach in Second Line
2.4. Looking Further Down the Line: Third Line
2.4.1. Evidence-Based Medicine: A Rational Approach in Third Line
3. FUTURE STEPS
3.1. Tailoring Therapy
4. SUMMARY
Conflicts of Interest
References
- Schiller, J.H. Small cell lung cancer: defining a role for emerging platinum drugs. Oncology 2002, 63, 105–14. [Google Scholar] [CrossRef] [PubMed]
- Stinchcombe, T.E.; Socinski, M.A. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009, 4, 243–50. [Google Scholar] [CrossRef] [PubMed]
- Ramalingam, S.; Belani, C.P. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 2007, 11, 245–57. [Google Scholar] [CrossRef] [PubMed]
- Schiller, J.H.; Harrington, D.; Belani, C.P.; et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346, 92–8. [Google Scholar] [CrossRef]
- Baggstrom, M.Q.; Stinchcombe, T.E.; Fried, D.B.; Poole, C.; Hensing, T.A.; Socinski, M.A. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a metaanalysis. J Thorac Oncol 2007, 2, 845–53. [Google Scholar] [CrossRef]
- Abratt, R.P.; Hart, G.J. 10-Year update on chemotherapy for nonsmall cell lung cancer. Ann Oncol 2006, 17 (suppl S5), v33–6. [Google Scholar] [CrossRef]
- Scagliotti, G.V.; Parikh, P.; von Pawel, J.; et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26, 3543–51. [Google Scholar] [CrossRef]
- Grønberg, B.H.; Bremnes, R.M.; Fløtten, O.; et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27, 3217–24. [Google Scholar] [CrossRef]
- Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3, 401–10. [Google Scholar] [CrossRef]
- Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58–62. [Google Scholar] [CrossRef]
- Ellis, L.M.; Hicklin, D.J. vegf-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8, 579–91. [Google Scholar] [CrossRef] [PubMed]
- Inai, T.; Mancuso, M.; Hashizume, H.; et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165, 35–52. [Google Scholar] [CrossRef] [PubMed]
- Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22, 2184–91. [Google Scholar] [CrossRef]
- Sandler, A.; Gray, R.; Perry, M.C.; et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355, 2542–50. [Google Scholar] [CrossRef]
- Reck, M.; von Pawel, J.; Zatloukal, P.; et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 2009, 27, 1227–34. [Google Scholar] [CrossRef]
- Laskin, J.; Crinò, L.; Tsai, C.; et al. MO19390 (sail): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (nsclc)—outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 2009, 4 (Suppl S1), S359. Available online: http://journals.lww.com/jto/toc/2009/09001 (accessed on 12 February 2010).
- Sandler, A.; Kong, G.; Strickland, D.; Johnson, D. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) Study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (nsclc) [abstract 133]. J Thorac Oncol 2008, 3 (Suppl 4), S283. Available online: http://journals.lww.com/jto/toc/2008/11001 (accessed on 12 February 2010).
- Hirsh, V. Emerging safety data for bevacizumab in advanced non–small-cell lung cancer. Clin Lung Cancer 2008, 9 (suppl 2), S62–S70. Available online: http://cigjournals.metapress.com/content/d43408q34506078m/ (accessed on 12 February 2010). [CrossRef]
- Crinò, L.; Mezger, J.; Griesinger, F.; Zhou, C.; Reck, M.M. MO19390 (sail): safety and efficacy of first-line bevacizumab (Bv)based therapy in advanced non-small cell lung cancer (nsclc) [abstract 8043]. Proc Am Soc Clin Oncol 2009, 27, 417s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstrac tID=30979 (accessed on 12 February 2010).
- Fischbach, N.; Spigel, D.; Brahmer, J.; et al.; on behalf of the aries Investigators Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (nsclc) from the aries study: a bevacizumab (BV) treatment observational cohort study (OCS) [abstract 8040]. Proc Am Soc Clin Oncol 2009, 27, 416s. Available online: www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst_detail_view&confID=65 &abstractID=30542 (accessed on 12 February 2010).
- Lynch, T.; Patel, T.; Dreisbach, L.; et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (nsclc): B3-03. J Thorac Oncol 2007, 2 (Suppl S4), S340–1. [Google Scholar] [CrossRef]
- Pirker, R.; Pereira, J.R.; Szczesna, A.; et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): an open-label randomised phase III trial. Lancet 2009, 373, 1525–31. [Google Scholar] [CrossRef] [PubMed]
- Scagliotti, G.V.; von Pawel, J.; Reck, M.; et al. Sorafenib plus carboplatin/paclitaxel in chemonaïve patients with stage IIIB–IV nonsmall-cell lung cancer (nsclc): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, escape (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in nsclc) trial. J Thor Oncol 2008, 3, S97–8. [Google Scholar]
- Krupitskaya, Y.; Wakelee, H. Vascular endothelial growth factor pathway. J Thor Oncol 2009, 4 (Suppl S3), S1071–3. [Google Scholar] [CrossRef]
- Rohr, U.; Augustus, S.; Lasserre, S.; Compton, P.; Huang, J. Safety of bevacizumab in patients with metastases to the central nervous system [abstract 2007]. Proc Am Soc Clin Oncol 2009, 27, 88s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstrac tID=30766 (accessed on 12 February 2010).
- European Medicines Agency (EMEA), Evaluation of Medicines for Human Use. In Assessment Report for Avastin. International Nonproprietary Name/Common Name: Bevacizumab. Procedure no. EMEA/H/C/582/II/0025; EMEA: London, U.K., 2008; Available online: www.ema.europa.eu/humandocs/PDFs/EPAR/avastin/Avastin-H-582-II-25-AR.pdf (accessed on 12 February 2010).
- Scagliotti, G.; Hanna, N.; Fossella, F.; et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase III studies. Oncologist 2009, 14, 253–63. [Google Scholar] [CrossRef]
- Mok, T.S.; Wu, Y.L.; Thongprasert, S.; et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009, 361, 947–57. [Google Scholar] [CrossRef]
- Mok, T.; To, K.F.; Srimunimimit, V.; et al. Clinical outcomes of patients with epidermal growth factor receptor (egfr) mutations in IPASS (Iressa Pan Asia Study) [abstract B9.5]. J Thorac Oncol 2009;4(suppl 1):S351. Available online: http://journals. lww.com/jto/toc/2009/09001 (accessed on 12 February 2010).
- Gridelli, C.; Maione, P.; Rossi, A.; et al. Potential treatment options after first-line chemotherapy for advanced nsclc: maintenance treatment or early second-line? Oncologist 2009, 14, 137–47. [Google Scholar] [CrossRef]
- Fidias, P.; Dakhil, S.; Lyss, A.; et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27, 591–8. [Google Scholar] [CrossRef]
- Belani, C.; Brodowicz, T.; Ciuleanu, T.; et al. Maintenance pemetrexed (Pem) plus best supportive care (bsc) versus placebo (Plac) plus bsc: a randomized phase III study in advanced nonsmall cell lung cancer (nsclc) [abstract CRA8000]. Proc Am Soc Clin Oncol 2009, 27, 806s. Available online: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view &confID=65&abstractID=33019 (accessed on 12 February 2010).
- Mezger, J.; von Pawel, J.; Reck, M. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (nsclc): results from an exploratory analysis of the avail study [abstract e19001]. Proc Am Soc Clin Oncol 2009, 27, e19001. Available online: www.asco.org/ASCOv2/Meetings/Abstracts? (accessed on 12 February 2010). [CrossRef]
- Cappuzzo, F.; Ciuleanu, T.; Stelmakh, L.; et al. SATURN: a doubleblind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced nsclc [abstract 8001]. Proc Am Soc Clin Oncol 2009, 27, 407s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstrac tID=32756 (accessed on 12 February 2010).
- Miller, V.; O’Connor, P.; Soh, C.; Kabbinavar, F.; on behalf of the ATLAS Investigators. A randomized, double-blind, placebocontrolled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002]. Proc Am Soc Clin Oncol 2009, 27, 799s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstrac tID=30819 (accessed on 12 February 2010).
- Cappuzzo, F.; Coudert, B.; Wierzbicki, R.; et al. Efficacy and safety of erlotinib as first-line maintenance in nsclc following non-progression with chemotherapy: results from the phase III SATURN study [abstract A2.1]. J Thorac Oncol 2009;4(suppl 1):S289. Available online: http://journals.lww.com/jto/toc/2009/09001 (accessed on 12 February 2010).
- Patel, J.; Bonomi, P.; Socinski, M.; et al. Treatment rationale and study design for the PointBreak Study: a randomized, openlabel phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous nonsmall-cell lung cancer. Clin Lung Cancer 2009, 10, 252–6. [Google Scholar]
- Waples, J.; Auerbach, M.; Steis, R.; Boccia, R.; Wiggans, R. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (an International Oncology Network study, #I-04-015) [abstract 19018]. Proc Am Soc Clin Oncol 2008, 26, 707s. Available online: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_ detail_view&confID=55&abstractID=32137 (accessed on 12 February 2010).
- Grothey, A.; Sugrue, M.M.; Purdie, D.M.; et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (briTE). J Clin Oncol 2008, 26, 5326–34. [Google Scholar] [CrossRef]
- Shepherd, F.A.; Dancey, J.; Ramlau, R.; et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18, 2095–103. [Google Scholar] [CrossRef] [PubMed]
- Fossella, F.V. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep 2000, 2, 96–101. [Google Scholar] [CrossRef]
- Hanna, N.; Shepherd, F.A.; Fossella, F.V.; et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22, 1589–97. [Google Scholar] [CrossRef]
- Shepherd, F.A.; Rodrigues Pereira, J.; Tan, E.H.; et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353, 123–32. [Google Scholar] [CrossRef]
- Novello, S.; Le Chevalier, T. Chemotherapy for non-small cell-lung cancer. Part 2: advanced disease. Oncology 2003, 17, 457–71. [Google Scholar] [PubMed]
- Haura, E. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001, 8, 326–36. [Google Scholar] [CrossRef] [PubMed]
- Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57, 4838–48. [Google Scholar] [PubMed]
- Pollack, V.A.; Savage, D.M.; Baker, D.A.; et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumour effects in athymic mice. J Pharmacol Exp Ther 1999, 291, 739–48. [Google Scholar] [CrossRef]
- Kim, E.; Hirsh, V.; Mok, T.; et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372, 1809–18. [Google Scholar] [CrossRef]
- Bezjak, A.; Tu, D.; Seymour, L.; et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study br.21. J Clin Oncol 2006, 24, 3831–7. [Google Scholar] [CrossRef]
- Reck, M.; Mali, P.; Arrieta, O.; Gottfried, M.; Van Meerbeeck, J. Global efficacy and safety results from the TRUST study of erlotinib monotherapy in > 7,000 patients with non-small-cell lung cancer (nsclc) [abstract 262P]. Ann Oncol 2008, 19 (suppl 8), viii100. [Google Scholar]
- Gutierrez, M.; Kummar, S.; Allen, D.; et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed nonsmall cell lung cancer (nsclc) [abstract 19084]. Proc Am Soc Clin Oncol 2008, 26, 712s. Available online: www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c onfID=55&abstractID=36323 (accessed on 12 February 2010).
- De Boer, R.; Arrieta, Ó.; Gottfried, M.; et al. Vandetanib plus pemetrexed vs. pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (nsclc): a randomized, double-blind phase III trial (ZEAL) [abstract 8010]. Proc Am Soc Clin Oncol 2009, 27, 409s. Available online: www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c onfID=65&abstractID=31867 (accessed on 12 February 2010).
- Natale, R.; Thongprasert, S.; Greco, F.; et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (nsclc) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) [abstract 8009]. Proc Am Soc Clin Oncol 2009, 27, 409s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstrac tID=31610 (accessed on 12 February 2010).
- Herbst, R.; Sun, Y.; Korfee, S.; et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (nsclc): a randomized, double-blind phase III trial (ZODIAC) [abstract CRA8003]. Proc Am Soc Clin Oncol 2009, 27, 807s. Available online: www. asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31495 (accessed on 12 February 2010).
- Di Maio, M.; Chiodini, P.; Georgoulias, V.; et al. Single agent vs. combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (nsclc): a meta-analysis of individual data of five randomized trials [abstract 8052]. Proc Am Soc Clin Oncol 2008, 26, 436s. Available online: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_ detail_view&confID=55&abstractID=31189 (accessed on 12 February 2010).
- Melosky, B.; Agulnik, J.; Assi, H. Retrospective practice review of metastatic non-small cell lung cancer treatment with secondline erlotinib. Curr Oncol 2008, 15, 279–85. [Google Scholar] [CrossRef] [PubMed]
- Yang, C.; Shih, J.; Chao, T.; et al. Use of BIBW 2992, a novel irreversible egfr/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating egfr mutations: preliminary results of a single-arm phase II clinical trial [abstract 8026]. Proc Am Soc Clin Oncol 2008, 26, 430s. Available online: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=55&abstrac tID=31779 (accessed on 12 February 2010).
- Herbst, R.S.; Johnson, D.H.; Mininberg, E.; et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23, 2544–55. [Google Scholar] [PubMed]
- Herbst, R.S.; O’Neill, V.J.; Fehrenbacher, L.; et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007, 25, 4743–50. [Google Scholar] [CrossRef]
- Herbst, R.; Stern, H.; Amler, L.; et al. Biomarker evaluation in the phase III, placebo-controlled, randomized BeTa Trial of bevacizumab and erlotinib for patients with advanced non-small cell lung cancer (nsclc) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes [abstract B2.1]. J Thorac Oncol 2009, 4 (Suppl S1), S323. Available online: http://journals. lww.com/jto/toc/2009/09001 (accessed on 12 February 2010).
© 2010 by the author. Multimed Inc.
Share and Cite
Hirsh, V. Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. Curr. Oncol. 2010, 17, 13-23. https://doi.org/10.3747/co.v17i2.549
Hirsh V. Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. Current Oncology. 2010; 17(2):13-23. https://doi.org/10.3747/co.v17i2.549
Chicago/Turabian StyleHirsh, Vera. 2010. "Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach" Current Oncology 17, no. 2: 13-23. https://doi.org/10.3747/co.v17i2.549
APA StyleHirsh, V. (2010). Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. Current Oncology, 17(2), 13-23. https://doi.org/10.3747/co.v17i2.549